D
PRECISION BIOSCIENCES INC
DTILCIK 0001357874NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends May 21
Period
FY 2025
Revenue
$34.26M
Net Income
$-45.72M
Total Assets
$154.42M
Equity
$92.25M
Shares Out
25.80M
Op. Cash Flow
$-65.84M
Business
Precision Biosciences is a clinical-stage gene editing company developing in vivo gene editing therapies using its proprietary ARCUS platform. The company's lead programs include PBGENE-HBV for chronic hepatitis B treatment and PBGENE-DMD for Duchenne muscular dystrophy, with additional partnered programs in ornithine transcarbamylase deficiency and oncological applications. The company operates globally with clinical trial sites across multiple countries including the United States, Europe, Asia-Pacific, and other regions.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 34 | 69 | 49 | 25 | 116 | |
| Research and development | 54 | 60 | 53 | 46 | 115 | |
| General and administrative | 32 | 35 | 39 | 41 | 40 | |
| Total operating expenses | 86 | 95 | 92 | 87 | 155 | |
| Operating loss | −52 | −26 | −44 | −62 | −39 | |
| Loss from equity method investment | −5 | −1 | −5 | −2 | 184,000 | |
| (Loss) gain on changes in other fair value adjustments | −3 | 258,000 | 1 | −510,000 | — | |
| Gain on change in fair value of warrant liability | 11 | 30 | — | — | — | |
| Interest expense | 1 | 2 | — | — | — | |
| Interest income | 4 | 7 | 8 | 3 | 208,000 | |
| Loss on disposal of assets | −421,000 | −436,000 | −461,000 | −30,000 | −26,000 | |
| Impairment charges | −36,000 | 0 | — | −11 | — | |
| Total other income | 6 | 33 | 1 | −11 | 9 | |
| (Loss) income from continuing operations | −47 | 7 | −43 | −73 | — | |
| Gain from discontinued operations | 885,000 | 0 | −19 | −39 | — | |
| Net (loss) income | −46 | 7 | −61 | −112 | −31 | |
| Basic (in USD per shares) | −3.56 | 1.05 | −15.96 | −38.1 | −0.52 | |
| Diluted (in USD per shares) | −3.56 | 1.04 | −15.96 | −38.1 | −0.52 | |
| Basic (in shares) | 13 | 7 | 4 | 3 | 59 | |
| Diluted (in shares) | 13 | 7 | 4 | 3 | 59 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 111 | 86 | 117 | 190 | 144 | |
| Accounts receivable | 0 | 229,000 | 901,000 | 720,000 | 488,000 | |
| Marketable securities | 5 | 413,000 | — | — | — | |
| Prepaid expenses | 3 | 6 | 6 | 6 | 17 | |
| Assets held for sale | 0 | 169,000 | 487,000 | — | — | |
| Contract asset | 0 | 1 | — | — | — | |
| Other current assets | 45,000 | 369,000 | 419,000 | 1 | 169,000 | |
| Total current assets | 119 | 95 | 136 | 199 | 162 | |
| Restricted cash | 26 | 23 | — | — | — | |
| Property, equipment, and softwarenet | 1 | 3 | 6 | 12 | 25 | |
| Intangible assetsnet | 1 | 622,000 | 400,000 | 731,000 | 2 | |
| Right-of-use assetsnet | 6 | 7 | 8 | 2 | 4 | |
| Investment in equity securities | 744,000 | 3 | 3 | 3 | 3 | |
| Note receivablenet | 0 | 5 | 5 | 7 | 7 | |
| Other assets | 206,000 | 221,000 | 225,000 | 226,000 | 5 | |
| Total assets | 154 | 136 | 160 | 238 | 211 | |
| Accounts payable | 296,000 | 1 | 3 | 653,000 | 1 | |
| Accrued compensation | 5 | 5 | 5 | 5 | 7 | |
| Accrued research and development expenses | 2 | 2 | 2 | 2 | — | |
| Deferred revenue | 0 | 3 | 12 | 46 | 21 | |
| Lease liabilities | 2 | 1 | 1 | 2 | 2 | |
| Other current liabilities | 649,000 | 989,000 | 2 | 745,000 | 977,000 | |
| Current liabilities of discontinued operations | 0 | 1 | 3 | 3 | — | |
| Total current liabilities | 9 | 15 | 50 | 60 | 36 | |
| Loan payable | 22 | 22 | — | — | — | |
| Deferred revenue | 0 | 23 | 73 | 83 | 67 | |
| Lease liabilities | 5 | 6 | 8 | 1 | 5 | |
| Warrant liability | 16 | 3 | — | — | — | |
| Contract liabilities | 10 | 10 | 10 | 10 | 10 | |
| Other noncurrent liabilities | 259,000 | 194,000 | 128,000 | 201,000 | 44,000 | |
| Total liabilities | 62 | 80 | 141 | 178 | 120 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Preferred stock: $0.0001 par value 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | — | |
| Common stock: $0.000005 par value 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 24,115,346 shares issued and 24,088,425 shares outstanding as of December 31, 2025; 8,229,730 shares issued and 8,202,715 shares outstanding as of December 31, 2024 | 1,000 | 1,000 | 1,000 | 1,000 | — | |
| Additional paid-in capital | 621 | 540 | 509 | 490 | 409 | |
| Accumulated deficit | −528 | −482 | −490 | −428 | −317 | |
| Treasury stock | −952,000 | −952,000 | −952,000 | −952,000 | −952,000 | |
| Total stockholders equity | 92 | 56 | 19 | 60 | 91 | |
| Total liabilities and stockholders equity | 154 | 136 | 160 | 238 | 211 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (loss) income | −46 | 7 | −61 | −112 | −31 | |
| Depreciation and amortization | 2 | 3 | 7 | 8 | 9 | |
| Share-based compensation | 10 | 13 | 14 | 19 | 17 | |
| (Gain) loss on disposal of assets | 421,000 | 436,000 | 563,000 | 106,000 | 26,000 | |
| Issuance of common stock in exchange for services | 259,000 | 0 | — | — | — | |
| Non-cash interest expense | 186,000 | 249,000 | 368,000 | 295,000 | 59,000 | |
| Amortization of right-of-use assets | 1 | 1 | 1 | 1 | 1 | |
| Loss (gain) on changes in other fair value adjustments | 3 | −258,000 | −1 | 510,000 | — | |
| Gain from disposal of business | −855,000 | 0 | — | — | — | |
| Amortization of discount on note receivable | −682,000 | −695,000 | −515,000 | −355,000 | −13,000 | |
| Gain on change in fair value of warrant liability | −11 | −30 | — | — | — | |
| Prepaid expenses | 3 | −464,000 | 1 | −962,000 | 6 | |
| Marketable securities | −5 | 2 | — | — | — | |
| Convertible note receivable | 0 | 10 | — | — | — | |
| Accounts receivable | 229,000 | 672,000 | −181,000 | −232,000 | 10 | |
| Contract asset | 1 | −1 | — | — | — | |
| Other assets and other current assets | 339,000 | −262,000 | 2 | 1 | −3 | |
| Accounts payable | −737,000 | −2 | 2 | 153,000 | 867,000 | |
| Other liabilities and other current liabilities | −2 | −2 | −724,000 | −2 | 1 | |
| Deferred revenue | −26 | −59 | −44 | 27 | −3 | |
| Lease liabilities | −1 | −1 | −946,000 | −2 | −2 | |
| Net cash used in operating activities | −66 | −58 | −84 | −46 | −11 | |
| Purchases of property, equipment and software | −85,000 | −250,000 | −2 | −3 | −5 | |
| Purchases of intangibles assets | −615,000 | −25,000 | −321,000 | — | −750,000 | |
| Proceeds from sale of equipment | 66,000 | 60,000 | 107,000 | — | — | |
| Net cash used in investing activities | −634,000 | −215,000 | 6 | −3 | −6 | |
| Proceeds from employee stock purchase plan | 218,000 | 249,000 | 370,000 | 443,000 | 804,000 | |
| Proceeds from offering of common stock and warrants through underwritten offering, net of issuance costs | 70 | 37 | — | — | — | |
| Proceeds from issuance of common stock through ATM facility, net of issuance cost | 24 | 12 | — | — | — | |
| Proceeds from offering of common stock to collaboration partners and licensees | 1 | 905,000 | — | 25 | 35 | |
| Repayment of revolving credit facility | 0 | −23 | — | — | — | |
| Borrowings from term loan debt facility, net of issuance costs paid to lender | 0 | 22 | — | — | 2 | |
| Net cash provided by financing activities | 95 | 50 | 5 | 95 | 71 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 29 | −8 | −73 | 46 | 54 | |
| Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities | 0 | 48,000 | 14,000 | 103,000 | 103,000 | |
| Intangible asset additions included in accounts payable and accrued expenses and other current liabilities | 300,000 | 250,000 | — | — | — | |
| Cash paid for interest | 1 | 2 | 2 | 824,000 | 68,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is PRECISION BIOSCIENCES INC's CIK number?
PRECISION BIOSCIENCES INC's SEC CIK number is 0001357874 (1357874). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PRECISION BIOSCIENCES INC's SEC filings?
All of PRECISION BIOSCIENCES INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PRECISION BIOSCIENCES INC last report earnings?
PRECISION BIOSCIENCES INC (DTIL) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-030123). This is PRECISION BIOSCIENCES INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is PRECISION BIOSCIENCES INC's most recent earnings 8-K?
PRECISION BIOSCIENCES INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001628280-26-030123. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PRECISION BIOSCIENCES INC's latest earnings 8-K →
Look up any company's CIK number →